P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

• E. Searle,
• H. Quach,
• S. Wong,
• L. Costa,
• C. Hulin,
• W. Janowski,
• J. Berdeja,
• S. Anguille,
• J. Matous,
• C. Touzeau,
• A. Michallet,
• M. Husnik,
• D. Vishwamitra,
• Z. Niu,
• J. Larsen,
• L. Chen,
• J. Goldberg,
• R. Popat,
• A. Spencer

Affiliations

E. Searle

1 The Chrisite Hospital NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

H. Quach

2 University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne, Australia

S. Wong

3 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

L. Costa

4 University of Alabama at Birmingham Hospital, Birmingham, AL, USA

C. Hulin

5 Hôpital Haut Leveque, University Hospital, Pessac, France

W. Janowski

6 Calvary Mater Newcastle, Waratah, Australia

J. Berdeja

7 Sarah Cannon Research Institute, Nashville, TN, USA

S. Anguille

8 Vaccine and Infectious Disease Institute, University of Antwerp, Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium

J. Matous

9 Colorado Blood Cancer Institute, Denver, CO, USA

C. Touzeau

10 Centre Hospitalier Universitaire de Nantes, Nantes, France

A. Michallet

11 Centre Hospitalier Lyon Sud, Hospices Civils, Lyon, France

M. Husnik

12 Janssen Research &Development, San Diego, CA, USA

D. Vishwamitra

13 Janssen Research & Development, Spring House, PA, USA

Z. Niu

13 Janssen Research & Development, Spring House, PA, USA

J. Larsen

13 Janssen Research & Development, Spring House, PA, USA

L. Chen

13 Janssen Research & Development, Spring House, PA, USA

J. Goldberg

13 Janssen Research & Development, Spring House, PA, USA

R. Popat

14 University College London Hospitals NHS Foundation Trust, Shanghai, China

A. Spencer

15 Monash University, Los Angeles, CA, USA